Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Photosoft Platform Expands to Eye Diseases Via Partnership 4 pages 384.4KB
Regulatory Filings Classification · 88% confidence The document is an ASX regulatory announcement detailing a strategic collaboration agreement with SANGMYUNG Innovation, including scope, funding of preclinical studies, and company commentary. It contains no financial statements, earnings figures, dividends, share issues, or voting results, nor is it a report itself. It is a general ASX filing that does not fit into more specific categories (M&A, financing, dividends, reports, etc.). Thus it is classified as a generic regulatory announcement (RNS).
2026-05-18 English
Correction to Appendix 3Y - Alistair Bennallack 5 pages 642.3KB
Director's Dealing Classification · 92% confidence The document is an ASX announcement titled “Appendix 3Y – Director’s Interest Notice” detailing a correction to a director’s disclosed interests, including the number of shares held indirectly via a superannuation fund and related transaction details. This aligns with the definition of a Director’s Dealing report (insider trades by company directors).
2026-05-10 English
Notification of cessation of securities - IVX 5 pages 16.1KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation of certain securities (options) for Invion Limited. It includes specific information about the securities that have ceased, the reason for cessation (expiry of options), and the updated issued capital following these changes. The document is a formal notification to the ASX about changes in the company's securities, specifically the cessation of certain options. This type of document is a regulatory announcement related to changes in the company's capital structure but does not describe new share issues or capital changes like stock splits or new share offerings. It is not a full financial report, earnings release, or management report. It is also not a report publication announcement or certification. The document fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement about securities cessation that does not fit more specific categories such as Share Issue/Capital Change (SHA) or Transaction in Own Shares (POS).
2026-04-30 English
Appendix 4C and Quarterly Activities Report - March 2026 8 pages 681.4KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'Activity Report and Cash Flow Report for the Quarter Ended 31 March 2026'. It includes detailed financial data such as cash flow statements, cash position, expenditure, and financing activities for the quarter. The presence of an Appendix 4C, which is a quarterly cash flow report required by ASX Listing Rule 4.7B, confirms this is a quarterly financial report. The document contains substantive financial data and analysis for a period shorter than a full fiscal year (quarterly). It is not merely an announcement of a report or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2026
2026-04-29 English
Notice of General Meeting/Proxy Form 157 pages 3.2MB
Proxy Solicitation & Information Statement Classification · 85% confidence The document is the full Notice of General Meeting (including Explanatory Statement and Proxy Form) issued to shareholders to solicit their votes on various resolutions at an upcoming virtual General Meeting. This corresponds exactly to the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-27 English
Bionnova 2026 Investor Presentation 17 pages 1.5MB
Investor Presentation Classification · 93% confidence The document is an ASX announcement clearly titled “INVESTOR PRESENTATION” and includes the full slide deck content (slides with charts, graphs, technology highlights, clinical data, etc.). It is not merely a brief notice of publication nor a transcript of a call, nor any financial report. Therefore it fits squarely under the “Investor Presentation” category (Code: IP).
2026-04-21 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.